
Key Points
- SEATCA presented Singapore Health Minister Ong Ye Kung with the inaugural Prakit Vathesatogkit Trailblazer Award in Bangkok.
- Singapore’s Ambassador to Thailand, Catherine Wong, accepted the award on his behalf.
- SEATCA cited leadership on regulating emerging tobacco and nicotine products and sharing policy experience across ASEAN.
- Amid rising student vaping, about 260 schools received nicotine test kits in 2025, and schools were required to report vaping cases.
- Tighter measures took effect on Sep 1, 2025, including listing etomidate (linked to Kpods) as a Class C drug and increasing penalties for students caught vaping.
2Firsts, Feb 6, 2026
According to CNA, Singapore’s Ministry of Health said Health Minister Ong Ye Kung was honoured by the Southeast Asian Tobacco Control Alliance (SEATCA) for leadership in advancing tobacco control policies, including measures to curb vaping. The inaugural Prakit Vathesatogkit Trailblazer Award was presented at SEATCA’s 25th anniversary event in Bangkok, Thailand, and accepted on his behalf by Singapore’s Ambassador to Thailand, Catherine Wong.
SEATCA said the award recognises Ong’s “bold and visionary leadership in tobacco control,” pointing to Singapore’s approach to banning and tightening regulation of emerging tobacco and nicotine products, as well as sharing policy experience with other ASEAN countries.
Singapore’s Ministry of Health noted that Singapore banned vaping from the outset in 2018 under the Tobacco (Control of Advertisements and Sale) Act (TCASA). Amid a sharp rise in student vaping, around 260 schools were issued nicotine test kits between March and August 2025, and educational institutions from primary schools to junior colleges were required to report vaping incidents.
MOH also highlighted that tighter anti-vaping measures took effect on Sep 1, 2025, including listing etomidate — an anaesthetic drug found in Kpods — as a Class C drug under the Misuse of Drugs Act, alongside increased penalties for students caught vaping.
Image Source: CNA
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com







